Gwang-Seong Choi1, Woo-Young Sim2, Hoon Kang3, Chang Hun Huh4, Yang Won Lee5, Sumitra Shantakumar6, Yu-Fan Ho6, Eun-Jeong Oh7, Mei Sheng Duh8, Wendy Y Cheng8, Priyanka Bobbili8, Philippe Thompson-Leduc8, Gary Ong9. 1. Department of Dermatology, Inha University College of Medicine, Incheon, Korea. 2. Department of Dermatology, Kyung Hee University Hospital at Gangdong, Seoul, Korea. 3. Department of Dermatology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. 4. Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, Korea. 5. Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea. 6. Vaccines R&D, Medical Affairs, GSK, Singapore. 7. GSK, Seoul, Korea. 8. Analysis Group, Inc., Boston, MA, United States. 9. Pharma Research and Development, Global Medical, GSK, Singapore. gary.p.ong@gsk.com.
Abstract
BACKGROUND: Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for long-term dutasteride use in AGA is lacking. OBJECTIVE: To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride. METHODS: This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness (improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period. RESULTS: Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (p<0.001) and more likely to have moderate/severe BASP classification at baseline (p=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, n=285), dutasteride-treated patients showed greater improvement in hair growth than finasteride-treated patients, as measured by the BASP basic M classification (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; p=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observation period were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%; p=0.201), although reports of AEs of special interest were equivalent (p<0.001). CONCLUSION: Dutasteride showed greater effectiveness than finasteride in improving BASP classification in treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.
BACKGROUND: Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for long-term dutasteride use in AGA is lacking. OBJECTIVE: To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride. METHODS: This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness (improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period. RESULTS: Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (p<0.001) and more likely to have moderate/severe BASP classification at baseline (p=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, n=285), dutasteride-treated patients showed greater improvement in hair growth than finasteride-treated patients, as measured by the BASP basic M classification (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; p=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observation period were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%; p=0.201), although reports of AEs of special interest were equivalent (p<0.001). CONCLUSION: Dutasteride showed greater effectiveness than finasteride in improving BASP classification in treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.
Authors: V Kanti; A Messenger; G Dobos; P Reygagne; A Finner; A Blumeyer; M Trakatelli; A Tosti; V Del Marmol; B M Piraccini; A Nast; U Blume-Peytavi Journal: J Eur Acad Dermatol Venereol Date: 2017-11-27 Impact factor: 6.166
Authors: Hee Chul Eun; Oh Sang Kwon; Je Ho Yeon; Hyo Seung Shin; Byung Yoon Kim; Byung In Ro; Han Kyong Cho; Woo Young Sim; Bark Lynn Lew; Won-Soo Lee; Hwa Young Park; Seung Phil Hong; Jae Hong Ji Journal: J Am Acad Dermatol Date: 2010-06-03 Impact factor: 11.527
Authors: I K Yeo; W S Jang; P K Min; H R Cho; S W Cho; N S Hong; J S Kang; D H Ki; H J Kim; Y C Kim; Y S Kim; I J Lee; S W Lee; E S Lim; D C Moon; K H Nam; C K Oho; S W Park; K S Shin; H C Yoo; C K Hong Journal: Clin Exp Dermatol Date: 2014-01 Impact factor: 3.470